Open access
Sep 2026
CasNano: An ultracompact CRISPR-Cas12f with a GC-rich PAM for epigenome editing with therapeutic potential
Clinical use of CRISPR-Cas proteins for genome engineering is constrained by their large size, limiting in vivo delivery. To address this, we engineered an ultracompact and versatile platform from a minimally active, 400-amino acid Cas12f protein from Blautia lenta. A multi-stage strategy of structure-guided protein mu...
Dongkyeong Kim, Chia-Wei Huang, Richard Pan et al.
· Molecular Therapy: Nucleic A... · 0 citations